Innolake Biopharm is based in China. It has raised $76M in total funding. Latest round: Pre-A.
Innolake Biopharm funding overview
Innolake Biopharm is based in China. Innolake Biopharm has raised $76M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Pre-A announced in April 2021. The round record for Innolake Biopharm runs through 2021; nothing later has been disclosed. Investors on record include WuXi Biologics, Qiantang Industrial Group, Zhongbo Juli. 3 distinct backers are named across the disclosed rounds.
Innolake Biopharm at a glance
Total raised
$76M
Latest round
Pre-A
Latest round date
April 2021
Headquarters
China
Notable investors
WuXi Biologics, Qiantang Industrial Group, Zhongbo Juli
Frequently asked about Innolake Biopharm funding
How much has Innolake Biopharm raised?
Innolake Biopharm has raised $76M in total disclosed funding across the rounds on record.
Who has invested in Innolake Biopharm?
WuXi Biologics, Qiantang Industrial Group, Zhongbo Juli are named among the investors backing Innolake Biopharm.
What was the latest Innolake Biopharm funding round?
The most recent disclosed round is a Pre-A, announced in April 2021.
Where is Innolake Biopharm based?
Innolake Biopharm is based in China.
When did Innolake Biopharm last raise?
The last disclosed Innolake Biopharm round closed in April 2021 at Pre-A.
Innolake Biopharm totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in China below to benchmark round size and investor mix.
